Theravance Biopharma (TBPH) Tops Q3 EPS by 19c

Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.73), $0.19 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $12.62 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• CrowdStrike Holdings Inc. (CRWD) Tops Q1 EPS by 3c, Offers Guidance
• CrowdStrike posts record ARR growth, raises full-year outlook